Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Brain/Spinal Cord Cancers

Imaging Study 21213
Assessing Brain Tumors with [18F] Fluoromisonidazole (FMISO) PET
Status Conditions Phase Study ID
Recruiting Brain Tumor Phase II 21213
Summary

To non-invasively assess the presence and extent of hypoxia in brain tumors in vivo, and to better understand the affect of tumor oxygenation on tumor growth and treatment response with the use of   [F18] fluoromisonidazole (FMISO) PET and BOLD MR imaging techniques.  


Investigator
Janet Eary, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • At least 18 years of age.
  • Have a confirmed diagnosis.
  • Planned to receive Bevacizumab.
  • Able to provide informed consent.
Exclusions (conditions that would prevent participation in this study)
  • Inability to provide informed consent.
  • Pregnancy.
  • Inability to lie still for the imaging study.
  • Weight over 350lbs, the weight limit of the tomograph table.
Last Updated
September 18, 2013
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.